Skip to search formSkip to main contentSkip to account menu

pimasertib

Known as: N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4- iodophenyl)amino]isonicotinamide Hydrochloride 
An orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity. Pimasertib selectively binds to and… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (2)

AS 703026MSC1936369
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Chemical-biology approach to delineate the mechanism of action of HIV-1 latency reversing agents
Prostratin exhibits potent HIV-1 latency reversing activity, yet its molecular mechanism of action has not been defined in detail… 
2016
2016
Abstract P5-04-02: The histone deacetylase inhibitor entinostat enhances the efficacy of the MEK inhibitor pimasertib against aggressive types of breast cancer through Noxa-mediated myeloid cell…
Purpose: Inflammatory breast cancer (IBC) and triple-negative breast cancer (TNBC) are the two most aggressive types of breast… 
2016
2016
Correction: The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy—Response
In this response to a letter to the editor (Clin Cancer Res 2016;22:2595), which was published in theMay 15, 2016, issue of… 
2015
2015
Abstract 2676: The MEK-inhibitor pimasertib is synergistic with PI3K-delta and BTK inhibitors in lymphoma models
Pimasertib (AS-703026) is a potent and highly selective ATP noncompetitive MEK1/2 inhibitor that has shown anti-tumor activity in… 
2014
2014
Abstract 739: The MEK-inhibitor pimasertib in B-cell lymphomas: Evaluation of the pre-clinical activity as single agent or in combination and identification of biomarkers of response
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Treatment of patients with lymphomas resistant/refractory…